Following the approval granted by FDA and TFDA last year, Medimaging Integrated Solution Inc. (MiiS)'s disposable endoscope has been approved in Japan. According to MiiS, their disposable endoscopes are currently sold under its own brand, but in the future will also strive for other ODM business, there are also plans to expand the European Union, Southeast Asia and other markets. It is expected that after approval, MiiS can continue to sell through the continuous co-operation of distribution channels, which will contribute to the growth of the company's business.

Recently, medical AI technology has attracted a high level of attention in the market. At present, MiiS's intelligent solutions applying AI technology consist of two products, one is retinal image analysis software, and the other is a wound care instrument, both of which use AI technology to read images of the affected area.

MiiS holds a relatively positive view of the medical device sales market this year, and expects that after inventories turnover is improved, it should be able to return to normal procurement status. The company's first-half consolidated revenue also came to about 265 million yuan, an annual increase of nearly 16%.